Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
20.30
-0.12 (-0.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
35
36
Next >
10 Health Care Stocks Whale Activity In Today's Session
↗
April 04, 2024
Via
Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
↗
March 28, 2024
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.
Via
Investor's Business Daily
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
↗
March 13, 2024
The threat is still emerging, but it could be significant.
Via
The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
↗
March 08, 2024
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients.
Via
Benzinga
Sarepta Therapeutics: Q4 Earnings Insights
↗
February 28, 2024
Via
Benzinga
A Preview Of Sarepta Therapeutics's Earnings
↗
February 27, 2024
Via
Benzinga
In-Depth Examination Of 13 Analyst Recommendations For Sarepta Therapeutics
↗
February 15, 2024
Via
Benzinga
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
↗
March 08, 2024
These stocks haven't been able to get much traction lately, even though they clearly deserve to now.
Via
The Motley Fool
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
↗
March 04, 2024
The upcoming regulatory decision on its latest drug could be big.
Via
The Motley Fool
Sarepta Therapeutics to Present at Upcoming Investor Conferences
March 04, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
↗
February 29, 2024
SRPT earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
February 28, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Is It Too Late to Buy Sarepta Therapeutics Stock?
↗
February 28, 2024
The company's hyperfocus on its core area could continue to be highly lucrative.
Via
The Motley Fool
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
↗
February 26, 2024
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.
Via
Benzinga
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
February 21, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For February 28, 2024
↗
February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
February 19, 2024
Via
Benzinga
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
↗
February 16, 2024
Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024.
Via
Benzinga
Why Sarepta Therapeutics Stock Is Soaring Today
↗
February 16, 2024
The biotech just scored a big FDA win with an even bigger one potentially coming by June.
Via
The Motley Fool
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
↗
February 16, 2024
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.
Via
Benzinga
Topics
Stocks
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
February 16, 2024
Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
February 16, 2024
Via
Benzinga
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
February 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
2 Magnificent Growth Stocks to Buy With $500
↗
February 15, 2024
No need to break the bank to invest in promising stocks.
Via
The Motley Fool
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
↗
February 12, 2024
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.
Via
Benzinga
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
